Get the Stockscreener App
499.88
5.73%
27.08
After Hours:
498.99
-0.89
-0.18%
Vertex Pharmaceuticals Inc stock is traded at $499.88, with a volume of 1.67M.
It is up +5.73% in the last 24 hours and up +9.79% over the past month.
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease. Additionally, Vertex is evaluating small-molecule inhibitors targeting acute and chronic pain using nonopioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
See More
Previous Close:
$472.80
Open:
$483
24h Volume:
1.67M
Relative Volume:
1.63
Market Cap:
$128.48B
Revenue:
$10.34B
Net Income/Loss:
$-489.90M
P/E Ratio:
37.50
EPS:
13.33
Net Cash Flow:
$-1.43B
1W Performance:
+6.28%
1M Performance:
+9.79%
6M Performance:
+24.63%
1Y Performance:
+32.88%
1-Day Range:
$474.00
$503.20
1-Week Range:
$463.14
$503.20
52-Week Range:
$341.90
$510.63
Vertex Pharmaceuticals Inc Stock (VRTX) Company Profile
Name
Vertex Pharmaceuticals Inc
Sector
Industry
Phone
(617) 341-6393
Address
50 NORTHERN AVENUE, BOSTON, MA
Vertex Pharmaceuticals Inc Stock (VRTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-10-24 | Resumed | Raymond James | Mkt Perform |
| Aug-05-24 | Downgrade | Barclays | Overweight → Equal Weight |
| Jun-27-24 | Initiated | Redburn Atlantic | Buy |
| Apr-11-24 | Upgrade | Evercore ISI | In-line → Outperform |
| Feb-15-24 | Initiated | Wolfe Research | Outperform |
| Feb-06-24 | Downgrade | Evercore ISI | Outperform → In-line |
| Feb-02-24 | Downgrade | Bernstein | Outperform → Mkt Perform |
| Jan-31-24 | Downgrade | Maxim Group | Buy → Hold |
| Jan-31-24 | Downgrade | Robert W. Baird | Neutral → Underperform |
| Jan-24-24 | Downgrade | Canaccord Genuity | Hold → Sell |
| Dec-14-23 | Reiterated | RBC Capital Mkts | Sector Perform |
| May-30-23 | Initiated | William Blair | Outperform |
| May-04-23 | Resumed | Piper Sandler | Overweight |
| Mar-21-23 | Initiated | Bernstein | Outperform |
| Jan-18-23 | Initiated | Canaccord Genuity | Hold |
| Jan-17-23 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Dec-19-22 | Downgrade | Jefferies | Buy → Hold |
| Jul-13-22 | Initiated | Cantor Fitzgerald | Overweight |
| Jun-01-22 | Upgrade | Maxim Group | Hold → Buy |
| May-23-22 | Initiated | SVB Leerink | Mkt Perform |
| May-06-22 | Downgrade | Robert W. Baird | Outperform → Neutral |
| May-03-22 | Upgrade | Morgan Stanley | Underweight → Equal-Weight |
| Feb-03-22 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Jan-27-22 | Reiterated | JP Morgan | Overweight |
| Jan-27-22 | Reiterated | Morgan Stanley | Underweight |
| Jan-27-22 | Reiterated | RBC Capital Mkts | Outperform |
| Jan-27-22 | Reiterated | Stifel | Hold |
| Jan-27-22 | Reiterated | Wolfe Research | Outperform |
| Jan-20-22 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Dec-09-21 | Initiated | Wells Fargo | Overweight |
| Nov-19-21 | Initiated | BMO Capital Markets | Market Perform |
| Nov-19-21 | Downgrade | Piper Sandler | Overweight → Neutral |
| Sep-09-21 | Downgrade | Stifel | Buy → Hold |
| Sep-07-21 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| Jul-20-21 | Downgrade | SVB Leerink | Mkt Perform → Underperform |
| Jul-19-21 | Resumed | Wolfe Research | Outperform |
| Jul-01-21 | Initiated | Raymond James | Mkt Perform |
| Jun-11-21 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Feb-23-21 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Feb-02-21 | Reiterated | H.C. Wainwright | Buy |
| Dec-30-20 | Initiated | Daiwa Securities | Outperform |
| Nov-30-20 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Nov-20-20 | Initiated | Bernstein | Outperform |
| Oct-28-20 | Initiated | UBS | Buy |
| Jul-31-20 | Reiterated | H.C. Wainwright | Buy |
| Jul-08-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Apr-30-20 | Reiterated | H.C. Wainwright | Buy |
| Apr-28-20 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Mar-04-20 | Initiated | Barclays | Overweight |
| Jan-31-20 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Nov-19-19 | Upgrade | Guggenheim | Neutral → Buy |
| Nov-12-19 | Initiated | SunTrust | Buy |
| Oct-17-19 | Resumed | BofA/Merrill | Buy |
| Sep-03-19 | Upgrade | Goldman | Neutral → Buy |
| Aug-01-19 | Downgrade | Needham | Buy → Hold |
| May-23-19 | Resumed | Citigroup | Buy |
| May-21-19 | Initiated | Credit Suisse | Outperform |
| Apr-12-19 | Initiated | Evercore ISI | In-line |
| Mar-26-19 | Upgrade | William Blair | Mkt Perform → Outperform |
| Mar-19-19 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Feb-06-19 | Downgrade | Maxim Group | Buy → Hold |
View All
Vertex Pharmaceuticals Inc Stock (VRTX) Latest News
Vertex Stock Flashes A Surprise Entry As Non-Opioid Pain Drug Looms - Investor's Business Daily
Vertex Pharmaceuticals (NASDAQ:VRTX) Given New $586.00 Price Target at UBS Group - MarketBeat
Vertex shares up after full-year product revenue guidance boost - Pharmaceutical Technology
Vertex Pharmaceuticals' (VRTX) "Overweight" Rating Reaffirmed at Cantor Fitzgerald - MarketBeat
Royal Bank of Canada Increases Vertex Pharmaceuticals (NASDAQ:VRTX) Price Target to $451.00 - MarketBeat
Vertex's Casgevy breaks ground with 1st commercial patient infusions as company readies another major launch for 2025 - FiercePharma
JPMorgan Chase & Co. Has Lowered Expectations for Vertex Pharmaceuticals (NASDAQ:VRTX) Stock Price - MarketBeat
VRTX Q3 Earnings & Sales Trump Estimates, '24 Sales View Raised - Yahoo Finance Australia
Morgan Stanley Raises Vertex Pharmaceuticals (NASDAQ:VRTX) Price Target to $476.00 - MarketBeat
Vertex Pharmaceuticals (NASDAQ:VRTX) Issues Earnings Results - MarketBeat
Investors reevaluate this year’s obesity darling - STAT
5 Top Stocks to Buy in November - The Motley Fool
Vertex Pharma reports Q3 2024 net income of $1.04bn - World Pharmaceutical Frontiers
Vertex tops Q3 forecast on strength of cystic fibrosis sales, raises full-year revenue guidance - PharmaLive
Vertex (VRTX) PT Raised to $451 at RBC Capital - StreetInsider.com
Vertex ups guidance again as results exceed estimates - The Pharma Letter
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Shares Sold by QRG Capital Management Inc. - MarketBeat
Earnings call: Vertex Pharmaceuticals Q3 2024 revenue climbs 12% - Investing.com
Earnings call: Vertex Pharmaceuticals Q3 2024 revenue climbs 12% By Investing.com - Investing.com UK
Vertex Pharmaceuticals Inc (VRTX) Q3 2024 Earnings Call Highligh - GuruFocus.com
Vertex Pharmaceuticals Inc (VRTX) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and ... - Yahoo Finance UK
Vertex Pharmaceuticals Reports Strong Q3 2024 Growth - TipRanks
Vertex Pharmaceuticals (VRTX) Q3 2024 Earnings Call Transcript - Yahoo Finance
Vertex Reports Third Quarter 2024 Financial Results - BioSpace
Vertex Pharma lifts annual revenue forecast on cystic fibrosis treatments strength - MSN
Vertex ups revenue guidance, eyes new 'multibillion-dollar franchise' - The Business Journals
Vertex Pharmaceuticals Beats Third-Quarter Estimates As Pain Treatment Looms - MSN
Vertex Pharmaceuticals Tops Q3 Estimates - The Motley Fool
Vertex Pharmaceuticals (VRTX) Q3 Earnings and Revenues Top Estimates - Yahoo Finance
Vertex: Q3 Earnings Snapshot - San Antonio Express-News
Vertex raises 2024 product revenue outlook following Q3 beats - Seeking Alpha
Vertex Pharmaceuticals Inc. Q3 Profit Increases, Beats Estimates - Nasdaq
Vertex Pharmaceuticals Raises Full-Year Outlook After 3Q Earnings - MarketWatch
Vertex Beats Quarterly Estimates As Pain Drug Looms - Investor's Business Daily
Vertex Pharmaceuticals Ups Revenue Forecast On Cystic Fibrosis Demand - Finimize
Vertex Pharma (VRTX) Tops Q3 EPS by 30c; raises guidance - StreetInsider.com
Vertex Pharma lifts annual revenue forecast on cystic fibrosis treatments strength | Today News - Mint
Vertex Pharmaceuticals Q3 24 Earnings Conference Call At 4:30 PM ET - Nasdaq
Jim Cramer Says Vertex Doing 'Lord's Work': Can Q3 Earnings Outshine Bearish Charts? - Benzinga
Janney Montgomery Scott LLC Lowers Holdings in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) - MarketBeat
US Bancorp DE Acquires 2,273 Shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) - MarketBeat
F M Investments LLC Lowers Holdings in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) - MarketBeat
9 Best Biotech Stocks Of November 2024 - Forbes
Vertex Pharma (VRTX) November 11 weekly option implied volatility into quarter results - StreetInsider.com
Vertex Pharma (VRTX) November 11 weekly 475 straddle priced into quarter results - StreetInsider.com
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Shares Sold by Pinnacle Associates Ltd. - MarketBeat
Vertex Pharmaceuticals Inc. stock underperforms Thursday when compared to competitors despite daily gains - MarketWatch
Vertex Gears Up to Report Q3 Earnings: Is a Beat in the Cards? - MSN
HM Payson & Co. Has $3.29 Million Holdings in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) - MarketBeat
T. Rowe Price Is 'One Of The Most Consistent' Companies: CramerCME Gr (NASDAQ:CME) - Benzinga
Cramer's Lightning Round: Vertex Pharmaceuticals is a buy - MSN
Vertex Pharmaceuticals Inc Stock (VRTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.07%
1.73%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):